BioBullets: The Aduhelm FDA approval controversy

This podcast accompanies Horizon 3 Biotech's BioBullets email for the 13th August 2021

Recent Podcasts

BioBullets: The Great Dispersion

BioBullets: The Aduhelm FDA approval controversy

Introduction to Horizon 3

Topical investment strategies in biotech

Accessing US markets – Nasdaq and FDA approval

Horizon 3 Biotech Fund and what drives investment decisions

Matt talks to Dimerix & Crucible Investments

Healthcare investment and the outlook for 2021

Introduction to Horizon3